Nathan A. Pennell, MD, PhD, on NSCLC: Lowering Genetic Testing Costs
2018 ASCO Annual MeetingNathan A. Pennell, MD, PhD, of the Cleveland Clinic, discusses the economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in newly diagnosed metastatic non–small cell lung cancer (Abstract 9031).
Related Videos
Courtney Denton Dinardo, MD, on AML: Treatment Study Results
Courtney Denton Dinardo, MD, of The University of Texas MD Anderson Cancer Center, discusses findings on the durable response with venetoclax in combination with decitabine or azac...
Andrew D. Seidman, MD, and Susan F. Dent, MD, on Breast Cancer: Analysis of the SANDPIPER Trial
Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Susan F. Dent, MD, of The Ottawa Hospital Cancer Centre, analyze the phase III study findings...
Nancy Davidson: Serendipity and Purpose (with Allen S. Lichter, MD)
Allen S. Lichter, MD, ASCO’s former Chief Executive Officer, talks with Nancy E. Davidson, MD, of Fred Hutchinson Cancer Research Center, the 2018 recipient of the...
David F. McDermott, MD, on RCC: Results of the KEYNOTE-427 Trial
David F. McDermott, MD, of Beth Israel Deaconess Medical Center, discusses study findings on pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carci...
Meletios A. Dimopoulos, MD, on Waldenström’s Macroglobulinemia
Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens, discusses phase III findings on ibrutinib/rituximab vs placebo/rituximab in Waldenström’s macrogl...
